TLDR: As OpenAI prepares to launch its GPT-5 model, Forbes explores the burgeoning landscape of Generative AI (GenAI) in healthcare, highlighting two primary strategies for monetization. The article discusses the rapid advancements of GenAI, its increasing capabilities in medical contexts, and the shift from traditional ‘narrow AI’ applications to more versatile generative models. It outlines how tech companies and clinicians are envisioning different pathways to integrate and profit from this transformative technology, aiming to address critical gaps in medical care.
Generative Artificial Intelligence (GenAI) is advancing at an unprecedented pace, with its capabilities reportedly doubling annually. Amidst this rapid evolution, OpenAI’s highly anticipated GPT-5 model is expected to launch within days, prompting a critical discussion on how this powerful technology will be monetized within the healthcare sector. Authored by Dr. Robert Pearl, a contributor focusing on the intersection of people, technology, and business in healthcare, a recent Forbes article delves into the emerging strategies.
Initially, when OpenAI released ChatGPT in late 2022, the medical community largely viewed it as a novelty, suitable perhaps for administrative tasks or basic reference but deemed too unreliable for clinical care. However, this perception has dramatically shifted in just a few years. Today, GenAI tools developed by tech giants like Google, Microsoft, and Nvidia are demonstrating performance that surpasses most physicians on national medical exams and clinical challenges. While these tools are not yet recommended for direct patient use without physician oversight, this restriction is anticipated to be lifted soon, signaling a significant paradigm shift in healthcare delivery.
Two distinct visions for monetizing GenAI in healthcare are currently emerging. The first approach mirrors a traditional tech playbook: technology companies developing new, FDA-approved tools specifically for diagnosis and treatment. This model focuses on creating regulated, high-assurance applications that can be integrated into existing clinical workflows.
The second vision is clinician-led and proposes a more accessible model. It envisions patients utilizing readily available and inexpensive large language models (LLMs) to manage their chronic diseases and assess new symptoms. This approach emphasizes empowering patients with tools for self-management and preliminary health assessments, potentially democratizing access to basic medical guidance.
To fully grasp the advantages of these approaches, it’s crucial to differentiate generative AI from the ‘narrow AI’ applications that have been the standard in medicine for over two decades. Narrow AI models are trained on vast datasets to solve specific, well-defined problems, primarily in visual specialties like radiology, pathology, and ophthalmology, where objective and replicable data is abundant. In contrast, generative AI offers broader capabilities, capable of creating new content and insights, making it applicable to more cognitive fields.
Also Read:
- Artificial Intelligence and Generative AI Driving Transformative Growth in Healthcare Sector
- Generative AI’s Expanding Footprint: Transforming Industries from Gaming to Finance
GenAI holds immense potential to address significant shortcomings in current medical care, such as suboptimal outcomes and affordability issues. For instance, in diabetes management, where fewer than half of patients achieve adequate disease control, GenAI could offer personalized guidance. Similarly, it could provide timely and affordable advice for new symptoms or assist patients in managing multiple chronic conditions, ultimately aiming to close critical gaps in healthcare delivery and improve patient outcomes.
